| 0.8992 -0.051 (-5.34%) | 01-26 14:53 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.17 | 1-year : | 1.34 |
| Resists | First : | 1 | Second : | 1.14 |
| Pivot price | 0.95  |
|||
| Supports | First : | 0.76 | Second : | 0.63 |
| MAs | MA(5) : | 0.94 |
MA(20) : | 0.92 |
| MA(100) : | 0.95 |
MA(250) : | 1.17 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 44.1 |
D(3) : | 46.8 |
| RSI | RSI(14): 48.7 |
|||
| 52-week | High : | 2.2 | Low : | 0.7 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ PDSB ] has closed above bottom band by 28.7%. Bollinger Bands are 22.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.99 - 1 | 1 - 1 |
| Low: | 0.91 - 0.92 | 0.92 - 0.93 |
| Close: | 0.94 - 0.95 | 0.95 - 0.96 |
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies, and cervical cancer. The company is also developing various product candidates, which are in preclinical trials, including PDS0102 T-cell receptor gamma alternate reading frame protein (TARP) for treating prostate and breast cancers; PDS0103 (MUC-1) for ovarian, colorectal, lung, and breast cancers; and PDS0104, which include Tyrosinase-related protein 2 for the treatment of melanoma. In addition, it is developing PDS0201 for treating tuberculosis; PDS0202, an influenza vaccine candidate; and PDS0203, a vaccine for the prevention of COVID-19. The company has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. PDS Biotechnology Corporation was founded in 2005 and is based in Florham Park, New Jersey.
Thu, 22 Jan 2026
PDS Biotech secures patent for cancer immunotherapy PDS0101 By Investing.com - Investing.com South Africa
Thu, 22 Jan 2026
PDS Biotechnology Secures Key Patent Strengthening PDS0101 Protection - TipRanks
Thu, 22 Jan 2026
PDS Biotechnology Corp Announces New U.S. Patent for PDS0101 - TradingView
Thu, 22 Jan 2026
PDS Biotech Announces New U.S. Patent Covering Technology Underlying PDS0101 - GlobeNewswire
Thu, 22 Jan 2026
New PDS0101 patent extends U.S. market protection toward 20 years - Stock Titan
Mon, 08 Dec 2025
PDS Biotechnology (PDSB) Upgraded to Buy: Here's Why - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 55 (M) |
| Shares Float | 48 (M) |
| Held by Insiders | 2.6 (%) |
| Held by Institutions | 10.5 (%) |
| Shares Short | 1,340 (K) |
| Shares Short P.Month | 1,820 (K) |
| EPS | -0.82 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.2 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -46.3 % |
| Return on Equity (ttm) | -221.9 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.59 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -32 (M) |
| Levered Free Cash Flow | -15 (M) |
| PE Ratio | -1.13 |
| PEG Ratio | 0 |
| Price to Book value | 4.57 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.56 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|